| scholarly article | Q13442814 |
| P2093 | author name string | Scott E Lukas | |
| Staci A Gruber | |||
| Kelly A Sagar | |||
| Megan T Racine | |||
| Mary K Dahlgren | |||
| Rosemary T Smith | |||
| P2860 | cites work | Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology | Q24602238 |
| Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia | Q24607361 | ||
| An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions | Q24627250 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| An Inventory for Measuring Depression | Q26778503 | ||
| Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials | Q26778552 | ||
| Brain development during childhood and adolescence: a longitudinal MRI study | Q28144698 | ||
| Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice | Q28258759 | ||
| Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease | Q28285648 | ||
| Factor structure of the Barratt impulsiveness scale | Q28288018 | ||
| Cannabinoids for Medical Use | Q29391539 | ||
| The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research | Q29547257 | ||
| The complex interaction between anxiety and cognition: insight from spatial and verbal working memory | Q30455991 | ||
| Effects of cannabis on the adolescent brain | Q30653619 | ||
| Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function | Q30654825 | ||
| Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States | Q31048322 | ||
| Neurocognition in college-aged daily marijuana users | Q33820148 | ||
| Considering Cannabis: The Effects of Regular Cannabis Use on Neurocognition in Adolescents and Young Adults | Q33855815 | ||
| Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report | Q33904362 | ||
| Half a century of research on the Stroop effect: an integrative review | Q34021872 | ||
| Persistent cannabis users show neuropsychological decline from childhood to midlife | Q34033362 | ||
| Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. | Q34141036 | ||
| A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation | Q34282923 | ||
| Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment | Q34304341 | ||
| The effect of cannabichromene on adult neural stem/progenitor cells | Q34363772 | ||
| Subjective effects to marijuana associated with marijuana use in community and clinical subjects | Q34399503 | ||
| Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. | Q34440282 | ||
| Cannabidiol as a Potential Treatment for Anxiety Disorders | Q34492624 | ||
| Medical Marijuana Use in Oncology: A Review | Q34518629 | ||
| Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. | Q34524284 | ||
| Profile of Mood States: The Factors and Their Physiological Correlates | Q34638811 | ||
| Prevalence of medical marijuana use in California, 2012. | Q45232572 | ||
| Controlled clinical trial of cannabidiol in Huntington's disease | Q45293556 | ||
| Cannabis use and cognitive function: 8-year trajectory in a young adult cohort | Q46089484 | ||
| Adolescent marijuana users have elevated risk-taking on the balloon analog risk task | Q46251445 | ||
| Practice effects and the use of alternate forms in serial neuropsychological testing | Q46492830 | ||
| Specific attentional dysfunction in adults following early start of cannabis use. | Q48234562 | ||
| Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being | Q48821406 | ||
| Cannabis dependence, cognitive control and attentional bias for cannabis words. | Q49056541 | ||
| The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. | Q50554671 | ||
| Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. | Q51411117 | ||
| Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. | Q51861083 | ||
| Neurocognitive consequences of marihuana--a comparison with pre-drug performance. | Q52056576 | ||
| The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. | Q53474628 | ||
| A simple objective technique for measuring flexibility in thinking. | Q55050827 | ||
| Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis. | Q55059515 | ||
| Reliability of a Timeline Method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations | Q68447241 | ||
| Applications To Become Registered Under the Controlled Substances Act To Manufacture Marijuana To Supply Researchers in the United States. Policy statement | Q95511372 | ||
| Cannabidiol for the treatment of psychosis in Parkinson's disease | Q34830827 | ||
| Opioids and the treatment of chronic pain: controversies, current status, and future directions | Q34846394 | ||
| Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. | Q35534902 | ||
| Neuropsychological sex differences associated with age of initiated use among young adult cannabis users | Q35638979 | ||
| Age of onset of marijuana use and executive function | Q35936433 | ||
| Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood | Q36044868 | ||
| The impact of initiation: Early onset marijuana smokers demonstrate altered Stroop performance and brain activation. | Q36132662 | ||
| Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: A three-year longitudinal study | Q36249140 | ||
| Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. | Q36496072 | ||
| Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence | Q36500689 | ||
| Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies | Q36563388 | ||
| Impulsivity, attention, memory, and decision-making among adolescent marijuana users. | Q36636731 | ||
| Marijuana Use Predicts Cognitive Performance on Tasks of Executive Function. | Q36717451 | ||
| Age of onset of marijuana use impacts inhibitory processing. | Q36860579 | ||
| An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California | Q36904018 | ||
| Efficacy of opioids for chronic pain: a review of the evidence | Q37198520 | ||
| Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity | Q37235845 | ||
| Impact of ADHD and cannabis use on executive functioning in young adults | Q37286873 | ||
| Association Between Lifetime Marijuana Use and Cognitive Function in Middle Age: The Coronary Artery Risk Development in Young Adults (CARDIA) Study | Q37413826 | ||
| Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users | Q37492203 | ||
| Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. | Q37640798 | ||
| Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity | Q37666477 | ||
| The effect of pain on cognitive function: a review of clinical and preclinical research | Q37826944 | ||
| The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review | Q38337699 | ||
| Early onset marijuana use is associated with learning inefficiencies | Q38394718 | ||
| Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy | Q38407322 | ||
| Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements | Q38423401 | ||
| Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. | Q38503842 | ||
| The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study | Q39176501 | ||
| Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. | Q39196812 | ||
| Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity | Q39211836 | ||
| Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | Q40151883 | ||
| Cannabis use before age 15 and subsequent executive functioning | Q43849098 | ||
| Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition | Q43970643 | ||
| Early-onset cannabis use and cognitive deficits: what is the nature of the association? | Q44360031 | ||
| P304 | page(s) | 355 | |
| P577 | publication date | 2016-10-13 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function | |
| P478 | volume | 7 |
| Q58088419 | A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age |
| Q62381376 | Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults: A Systematic Review and Meta-analysis |
| Q89468008 | Cannabinoids in the descending pain modulatory circuit: Role in inflammation |
| Q92310219 | Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives |
| Q58557888 | Combined ∆-tetrahydrocannabinol and moderate alcohol administration: effects on ingestive behaviors in adolescent male rats |
| Q33700887 | Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition |
| Q58775143 | Emerging Evidence for Cannabis' Role in Opioid Use Disorder |
| Q92695808 | Long-term medical cannabis use and risk factors for diversion: Report on physician's guidance and patients' behaviour |
| Q89389849 | Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research |
| Q89945819 | Medical Cannabis Reduced Agitation in Acquired Brain Injury: A Case Study |
| Q92707688 | Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review |
| Q90017225 | Medicinal versus Recreational Cannabis Use among Returning Veterans |
| Q47827750 | The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment. |
Search more.